Selective CRAF Inhibition Elicits Transactivation
Charles W Morgan1, Ian L Dale2, Andrew P Thomas3
1Medical Research Council Laboratory of Molecular Biology, Cambridge CB2 0QH, United Kingdom.
Abstract:
Discovering molecules that regulate closely related protein isoforms is challenging, and in many cases the consequences of isoform-specific pharmacological regulation remains unknown. RAF isoforms are commonly mutated oncogenes that serve as effector kinases in MAP kinase signaling. BRAF/CRAF heterodimers are believed to be the primary RAF signaling species, and many RAF inhibitors lead to a "paradoxical activation" of RAF kinase activity through transactivation of the CRAF protomer; this leads to resistance mechanisms and secondary tumors. It has been hypothesized that CRAF-selective inhibition might bypass paradoxical activation, but no CRAF-selective inhibitor has been reported and the consequences of pharmacologically inhibiting CRAF have remained unknown. Here, we use bio-orthogonal ligand tethering (BOLT) to selectively target inhibitors to CRAF. Our results suggest that selective CRAF inhibition promotes paradoxical activation and exemplify how BOLT may be used to triage potential targets for drug discovery before any target-selective small molecules are known.
Insights
Targeting CRAF (a RAF kinase) selectively may paradoxically activate RAF signaling, contrary to hypotheses. This study used bio-orthogonal ligand tethering (BOLT) to investigate CRAF inhibition, revealing implications for cancer drug discovery.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Discovering isoform-specific drugs is difficult, with unknown consequences of isoform regulation.
- RAF kinases (BRAF, CRAF) are key in MAP kinase signaling and often mutated in cancer.
- Current RAF inhibitors can cause paradoxical activation via CRAF, leading to resistance.
Purpose of the Study:
- To investigate the effects of selective CRAF inhibition.
- To explore if CRAF-selective inhibition bypasses paradoxical activation.
- To demonstrate the utility of bio-orthogonal ligand tethering (BOLT) for target validation.
Main Methods:
- Utilized bio-orthogonal ligand tethering (BOLT) to selectively target inhibitors to CRAF.
- Investigated the downstream signaling consequences of selective CRAF inhibition.
Main Results:
- Selective CRAF inhibition was found to promote paradoxical activation of RAF signaling.
- This finding challenges the hypothesis that CRAF-selective inhibition would bypass paradoxical activation.
- Demonstrated BOLT as a method for early-stage target triage in drug discovery.
Conclusions:
- Selective CRAF inhibition can lead to paradoxical activation, similar to broader RAF inhibition.
- BOLT is a valuable tool for assessing the consequences of targeting specific protein isoforms early in drug discovery.
- Understanding CRAF's role is crucial for developing effective cancer therapies and overcoming drug resistance.
Related Concept Videos
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Co-activators and Co-repressors
RNA Polymerase II Accessory Proteins
Eukaryotic Transcription Activators
The binding domains are capable of recognizing and interacting with regulatory sequences on the DNA. These...
Master Transcription Regulators
Cell Specific Gene Expression


